ADAP earnings call for the period ending June 30, 2019.
News & Analysis: Adaptimmune Therapeutics
See if these oncology-driven drugmakers have what it takes to recover from recent setbacks.
Find out why these stocks climbed on a mixed day for Wall Street.
A handful of responses from cancer patients with solid tumors pleased investors.
MannKind and Northwest Biotherapeutics have attracted ginormous short positions this year. Is the Street wrong about these stocks?
Small-cap biopharma Adaptimmune Therapeutics saw its stock sink in July. Is this speculative pharma now a good long-term buy?